Mobile

A trial looking at the treatment of SOF/GS-5816 for 12 weeks against the treatment of Sofosbuvir and Ribavirin for 24 weeks in patients with hepatitis C infection

Update Il y a 4 ans
Reference: EUCTR2014-001682-27

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

The primary objectives of this study are: * To compare the efficacy of treatment with sofosbuvir (SOF)/GS-5816 fixed dose combination (FDC) for 12 weeks with that of SOF + ribavirin (RBV) for 24 weeks as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR12) * To evaluate the safety and tolerability of each treatment regimen

Inclusion criteria

  • Chronic hepatitis C virus infection

Links